Back to Search
Start Over
A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease
- Source :
- Neurological Sciences. 41:2267-2270
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- EPM2A has been certified as a causative gene in patients with Lafora disease (LD), which is a rare autosomal recessive and severe form of progressive myoclonus epilepsy. LD classically starts in adolescence, characterized by various types of seizure with myoclonic seizure as the main type. Typically within 10 years, intractable seizure attack, rapidly progressing dementia, and a vegetative state were present. LD is particularly frequently found in Mediterranean countries. Here, we report a Chinese family with a novel compound heterozygous mutation in the EPM2A gene, characterized by recurrent vomiting, intractable epilepsy, and progressive cognitive decline.
- Subjects :
- Male
China
medicine.medical_specialty
Pediatrics
Neurology
Adolescent
Ubiquitin-Protein Ligases
Intractable epilepsy
Dermatology
Progressive myoclonus epilepsy
Compound heterozygosity
Lafora disease
03 medical and health sciences
0302 clinical medicine
Seizures
medicine
Humans
Dementia
030212 general & internal medicine
Chinese family
business.industry
General Medicine
Protein Tyrosine Phosphatases, Non-Receptor
medicine.disease
Psychiatry and Mental health
Lafora Disease
Mutation
Mutation (genetic algorithm)
Neurology (clinical)
business
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 15903478 and 15901874
- Volume :
- 41
- Database :
- OpenAIRE
- Journal :
- Neurological Sciences
- Accession number :
- edsair.doi.dedup.....25704ffa6f5e2c1442d2a45f6d690199
- Full Text :
- https://doi.org/10.1007/s10072-020-04377-7